Extended-Release Buprenorphine Not Necessarily Cost-Effective
Consumer HealthDay -

TUESDAY, Sept. 19, 2023 (HealthDay News) -- For patients with opioid use disorder (OUD), treatment with extended-release buprenorphine is not cost-effective when transmucosal buprenorphine is available, according to a study published online Sept. 13 in JAMA Network Open.Juliet M. Flam-Ross, from Boston Medical Center, and colleagues examined the cost-effectiveness of extended-release buprenorphine versus transmucosal buprenorphine. The evaluation simulated the lifetime of a closed cohort of...

Related Articles

Latest in News

More from Consumer HealthDay | General Health Prescription Drugs Pain Managment Opioids Public Health Health Costs General health Prescription drugs Pain managment Public health Health costs